Trial reportScientific reports2025
Encapsulated oil palm phenolics lower blood pressure and improve antioxidant status in healthy adults: a phase one trial.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Oil Palm Phenolics (OPP), derived from by-products of oil palm fruit processing, contain bioactive polyphenols with nutraceutical benefits. While the optimal dose has been suggested for both liquid and spray-dried preparations, their efficacy in humans requires further investigation. This study assesses the effects of encapsulated OPP powder on cardiovascular and antioxidant (AOX) parameters in healthy individuals. A double-blind, placebo-controlled trial with 97 healthy volunteers randomized into four groups: placebo, 250 mg, 1000 mg, and 1500 mg/d spray-dried encapsulated OPP for 60 days. Primary outcomes included changes in lipid profiles, systolic (SBP) and diastolic blood pressure (DBP), and AOX markers including glutathione peroxidase (GSH-Px), glutathione reductase (GR), total superoxide dismutase (T-SOD), and total AOX capacity (T-AOC). 250 mg/d OPP significantly reduced SBP and DBP at day 60 compared to baseline (SBP: p = 0.017; DBP: p < 0.001). T-AOC improved significantly with the 1500 mg/d at day 30 (p = 0.038). Higher doses OPP (1000 and 1500 mg/d) preserved GSH-Px levels, while placebo and 250 mg/d OPP showed declines. Encapsulated OPP improved AOX status without affecting lipid profiles while improves BP at low doses. These findings support its development as a dietary supplement, warranting further investigation into optimized dosages and long-term effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.